%0 Generic
%A H., Imai
%A K., Komine
%A S., Takahashi
%A K., Saijo
%A Y., Okada
%A A., Kobayashi
%A A., Okita
%A S., Chikamatsu
%A Y., Kasahara
%A M., Takahashi
%A T., Oishi
%A H., Shirota
%A H., Shimodaira
%A C., Ishioka
%D 2016
%T Supplementary Material for: Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma
%U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Efficacy_and_Safety_Assessment_of_Paclitaxel_in_Patients_with_Docetaxel-Resistant_Esophageal_Squamous_Cell_Carcinoma/4028808
%R 10.6084/m9.figshare.4028808.v1
%2 https://karger.figshare.com/ndownloader/files/6487383
%2 https://karger.figshare.com/ndownloader/files/6487386
%2 https://karger.figshare.com/ndownloader/files/6487389
%2 https://karger.figshare.com/ndownloader/files/6487392
%K Esophageal cancer
%K Paclitaxel
%K Docetaxel
%K Cross-resistance
%X
Background: Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Methods: Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment. Results: A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively. Conclusions: There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma.
%I Karger Publishers